1
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
van den Bent MJ: Interobserver variation
of the histopathological diagnosis in clinical trials on glioma: A
clinician's perspective. Acta Neuropathol. 120:297–304. 2010.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Joseph JV, Balasubramaniyan V, Walenkamp A
and Kruyt FA: TGF-β as a therapeutic target in high grade gliomas -
promises and challenges. Biochem Pharmacol. 85:478–485. 2013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Nicolaidis S: Biomarkers of glioblastoma
multiforme. Metabolism. 64 Suppl 1:S22–S27. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long non-coding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Caley DP, Pink RC, Trujillano D and Carter
DR: Long non-coding RNAs, chromatin, and development. Sci World J.
10:90–102. 2010. View Article : Google Scholar
|
8
|
Wapinski O and Chang HY: Long non-coding
RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Nagano T and Fraser P: No-nonsense
functions for long noncoding RNAs. Cell. 145:178–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Gibb EA, Brown CJ and Lam WL: The
functional role of long non-coding RNA in human carcinomas. Mol
Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lee JT: Epigenetic regulation by long
non-coding RNAs. Science. 338:1435–1439. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Takayama K, Horie-Inoue K, Katayama S,
Suzuki T, Tsutsumi S, Ikeda K, Urano T, Fujimura T, Takagi K,
Takahashi S, et al: Androgen-responsive long noncoding RNA CTBP1-AS
promotes prostate cancer. EMBO J. 32:1665–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yang X, Song JH, Cheng Y, Wu W, Bhagat T,
Yu Y, Abraham JM, Ibrahim S, Ravich W, Roland BC, et al: Long
non-coding RNA HNF1A-AS1 regulates proliferation and migration in
oesophageal adenocarcinoma cells. Gut. 63:881–890. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Guo H, Wu L, Yang Q, Ye M and Zhu X:
Functional linc-POU3F3 is overexpressed and contributes to
tumorigenesis in glioma. Gene. 554:114–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang X, Sun S, Pu JK, Tsang AC, Lee D,
Man VO, Lui WM, Wong ST and Leung GK: Long non-coding RNA
expression profiles predict clinical phenotypes in glioma.
Neurobiol Dis. 48:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang XQ, Sun S, Lam KF, Kiang KM, Pu JK,
Ho AS, Lui WM, Fung CF, Wong TS and Leung GK: A long non-coding RNA
signature in glioblastoma multiforme predicts survival. Neurobiol
Dis. 58:123–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Maleszewska M and Kaminska B: Deregulation
of histone-modifying enzymes and chromatin structure modifiers
contributes to glioma development. Future Oncol. 11:2587–2601.
2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lee J, Solomon DA and Tihan T: The role of
histone modifications and telomere alterations in the pathogenesis
of diffuse gliomas in adults and children. J Neurooncol. 132:1–11.
2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Conway E, Healy E and Bracken AP: PRC2
mediated H3K27 methylations in cellular identity and cancer. Curr
Opin Cell Biol. 37:42–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wu J, Hu L, Du Y, Kong F and Pan Y:
Prognostic role of LSD1 in various cancers: Evidence from a
meta-analysis. Onco Targets Ther. 8:2565–2570. 2015.PubMed/NCBI
|
22
|
Tsai MC, Manor O, Wan Y, Mosammaparast N,
Wang JK, Lan F, Shi Y, Segal E and Chang HY: Long non-coding RNA as
modular scaffold of histone modification complexes. Science.
329:689–693. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Nie F, Yu X, Huang M, Wang Y, Ma H, Wang
Z, De W and Sun M: Long noncoding RNA ZFAS1 promotes gastric cancer
cells proliferation by epigenetically repressing KLF2 and NKD2
expression. Oncotarget. 8:38227–38238. 2017.PubMed/NCBI
|
24
|
Li W, Sun M, Zang C, Ma P, He J, Zhang M,
Huang Z, Ding Y and Shu Y: Upregulated long non-coding RNA
AGAP2-AS1 represses LATS2 and KLF2 expression through interacting
with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell Death
Dis. 7:e22252016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: a summary.
Acta Neuropathol. 131:803–820. 2016.doi: 10.1007/s00401-016-1545-1.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO Classification of Tumours of the Central Nervous System. Acta
Neuropathol. 114:97–109. 2007.doi: 10.1007/s00401-007-0243-4.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Song S, Fajol A, Tu X, Ren B and Shi S:
miR-204 suppresses the development and progression of human
glioblastoma by targeting ATF2. Oncotarget. 7:70058–70065.
2016.PubMed/NCBI
|
28
|
Arita H, Narita Y, Matsushita Y, Fukushima
S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S and Ichimura
K: Development of a robust and sensitive pyrosequencing assay for
the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol.
32:22–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Arita H, Narita Y, Fukushima S, Tateishi
K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP,
Kawahara N, et al: Upregulating mutations in the TERT promoter
commonly occur in adult malignant gliomas and are strongly
associated with total 1p19q loss. Acta Neuropathol. 126:267–276.
2013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Mulholland S, Pearson DM, Hamoudi RA,
Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund
LM, Collins VP, et al: MGMT CpG island is invariably methylated in
adult astrocytic and oligodendroglial tumors with IDH1 or IDH2
mutations. Int J Cancer. 131:1104–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Okita Y, Narita Y, Miyakita Y, Ohno M,
Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T and Shibui
S: IDH1/2 mutation is a prognostic marker for survival and predicts
response to chemotherapy for grade II gliomas concomitantly treated
with radiation therapy. Int J Oncol. 41:1325–1336. 2012. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhang Q, Matsuura K, Kleiner DE, Zamboni
F, Alter HJ and Farci P: Analysis of long non-coding RNA expression
in hepatocellular carcinoma of different viral etiology. J Transl
Med. 14:3282016. View Article : Google Scholar : PubMed/NCBI
|
33
|
Chen ZH, Hu HK, Zhang CR, Lu CY, Bao Y,
Cai Z, Zou YX, Hu GH and Jiang L: Down-regulation of long
non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell
proliferation, migration, and invasion in malignant glioma cells.
Am J Transl Res. 8:4106–4119. 2016.PubMed/NCBI
|
34
|
Liang L, Wong CM, Ying Q, Fan DN, Huang S,
Ding J, Yao J, Yan M, Li J, Yao M, et al: MicroRNA-125b
suppressesed human liver cancer cell proliferation and metastasis
by directly targeting oncogene LIN28B2. Hepatology. 52:1731–1740.
2010. View Article : Google Scholar : PubMed/NCBI
|
35
|
He Z, Huang C, Lin G and Ye Y:
siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits
the invasion of human lung cancer SPC-A1 cells. Oncol Rep.
35:1933–1940. 2016. View Article : Google Scholar : PubMed/NCBI
|
36
|
Turkalp Z, Karamchandani J and Das S: IDH
mutation in glioma: New insights and promises for the future. JAMA
Neurol. 71:1319–1325. 2014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Zhang YA, Ma X, Sathe A, Fujimoto J,
Wistuba I, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, et al:
Validation of SCT methylation as a hallmark biomarker for lung
cancers. J Thorac Oncol. 11:346–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
39
|
Malmström A, Grønberg BH, Marosi C, Stupp
R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi
ME, et al Nordic Clinical Brain Tumour Study Group (NCBTSG), :
Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with
glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol.
13:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
40
|
Wick W, Platten M, Meisner C, Felsberg J,
Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M,
et al NOA-08 Study Group of Neuro-oncology Working Group (NOA) of
German Cancer Society, : Temozolomide chemotherapy alone versus
radiotherapy alone for malignant astrocytoma in the elderly: The
NOA-08 randomised, phase 3 trial. Lancet Oncol. 13:707–715. 2012.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Arita H, Yamasaki K, Matsushita Y,
Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M,
Shimizu S, et al: A combination of TERT promoter mutation and MGMT
methylation status predicts clinically relevant subgroups of newly
diagnosed glioblastomas. Acta Neuropathol Commun. 4:792016.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Chinaranagari S, Sharma P and Chaudhary J:
EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4
in prostate cancer. Oncotarget. 5:7172–7182. 2014. View Article : Google Scholar : PubMed/NCBI
|
43
|
Betancur JG and Tomari Y: Cryptic
RNA-binding by PRC2 components EZH2 and SUZ12. RNA Biol.
12:959–965. 2015. View Article : Google Scholar : PubMed/NCBI
|
44
|
Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei
JS, Marquez VE, Bates SE, Jin Q, Khan J, et al: EZH2 mediates
epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU,
RUNX3, and NGFR. Cancer Res. 72:315–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
45
|
Wu Z, Wang Q, Wang L, Li G, Liu H, Fan F,
Li Z, Li Y and Tu Y: Combined aberrant expression of Bmi1 and EZH2
is predictive of poor prognosis in glioma patients. J Neurol Sci.
335:191–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
46
|
Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu
P and Kang C: EZH2 is a negative prognostic factor and exhibits
pro-oncogenic activity in glioblastoma. Cancer Lett. 356:929–936.
2015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Zhang Y, Yu X, Chen L, Zhang Z and Feng S:
EZH2 overexpression is associated with poor prognosis in patients
with glioma. Oncotarget. 8:565–573. 2017.PubMed/NCBI
|
48
|
Huang M, Hou J, Wang Y, Xie M, Wei C, Nie
F, Wang Z and Sun M: Long noncoding RNA LINC00673 is activated by
SP1 and exerts oncogenic properties by interacting with LSD1 and
EZH2 in gastric cancer. Mol Ther. 25:1014–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
49
|
Sun CC, Li SJ, Li G, Hua RX, Zhou XH and
Li DJ: Long intergenic non-coding RNA 00511 acts as an oncogene in
non-small-cell lung cancer by binding to EZH2 and suppressing p57.
Mol Ther Nucleic Acids. 5:e3852016. View Article : Google Scholar : PubMed/NCBI
|
50
|
Ding J, Xie M, Lian Y, Zhu Y, Peng P, Wang
J, Wang L and Wang K: Long non-coding RNA HOXA-AS2 represses P21
and KLF2 expression transcription by binding with EZH2, LSD1 in
colorectal cancer. Oncogenesis. 6:e2882017. View Article : Google Scholar : PubMed/NCBI
|
51
|
Du WW, Yang W, Liu E, Yang Z, Dhaliwal P
and Yang BB: Foxo3 circular RNA retards cell cycle progression via
forming ternary complexes with p21 and CDK2. Nucleic Acids Res.
44:2846–2858. 2016. View Article : Google Scholar : PubMed/NCBI
|
52
|
Liu F, Tong D, Li H, Liu M, Li J, Wang Z
and Cheng X: Bufalin enhances antitumor effect of paclitaxel on
cervical tumorigenesis via inhibiting the integrin α2/β5/FAK
signaling pathway. Oncotarget. 7:8896–8907. 2016. View Article : Google Scholar : PubMed/NCBI
|
53
|
Ivkovic S, Canoll P and Goldman JE:
Constitutive EGFR signaling in oligodendrocyte progenitors leads to
diffuse hyperplasia in postnatal white matter. J Neurosci.
28:914–922. 2008. View Article : Google Scholar : PubMed/NCBI
|
54
|
Galvez-Contreras AY, Quiñones-Hinojosa A
and Gonzalez-Perez O: The role of EGFR and ErbB family related
proteins in the oligodendrocyte specification in germinal niches of
the adult mammalian brain. Front Cell Neurosci. 7:2582013.
View Article : Google Scholar : PubMed/NCBI
|
55
|
Huse JT and Holland EC: Targeting brain
cancer: Advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
56
|
Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan
G and Jiang Y: HULC long non-coding RNA silencing suppresses
angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling
pathway in human gliomas. Oncotarget. 7:14429–14440. 2016.
View Article : Google Scholar : PubMed/NCBI
|
57
|
Wang Q, Cheng F, Ma TT, Xiong HY, Li ZW,
Xie CL, Liu CY and Tu ZG: Interleukin-12 inhibits the
hepatocellular carcinoma growth by inducing macrophage polarization
to the M1-like phenotype through downregulation of Stat-3. Mol Cell
Biochem. 415:157–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
58
|
Sun L, Zhang Q, Li Y, Tang N and Qiu X:
CCL21/CCR7 up-regulate vascular endothelial growth factor-D
expression via ERK pathway in human non-small cell lung cancer
cells. Int J Clin Exp Pathol. 8:15729–15738. 2015.PubMed/NCBI
|
59
|
Jansen M, Yip S and Louis DN: Molecular
pathology in adult gliomas: Diagnostic, prognostic, and predictive
markers. Lancet Neurol. 9:717–726. 2010. View Article : Google Scholar : PubMed/NCBI
|
60
|
Yang P, Qiu Z, Jiang Y, Dong L, Yang W, Gu
C, Li G and Zhu Y: Silencing of cZNF292 circular RNA suppresses
human glioma tube formation via the Wnt/β-catenin signaling
pathway. Oncotarget. 7:63449–63455. 2016. View Article : Google Scholar : PubMed/NCBI
|